Tuesday's Health Winners & Losers

Citigroup upgraded biopharmaceutical company Adolor (ADLR) to hold from sell, citing a decision from the company's partner GlaxoSmithKline (GSK) to continue with a late-stage program for its bowel treatment drug, Entereg. The firm also upped Adolor's stock price target to $10 from $5. Shares were recently adding 41 cents, or 4.8%, to $9.01.

Nabi Biopharmaceuticals (NABI) was higher after the company posted a narrower-than-expected fourth-quarter loss late Monday. The company also announced plans to cut its operations into two business units, Nabi Biologics and Nabi Pharmaceuticals. The stock was rising 22 cents, or 4.6%, at $5.05.

On the other hand, Emisphere Technologies (EMIS) tumbled 10.3% after the company attached an addendum to its fourth-quarter and year-end results. The addendum included a note from Emisphere's accountant that raised doubts that the company had the capital resources and ability to operate after September. Emisphere was off 47 cents to $4.10.

Merck (MRK) inched lower after a jury in New Jersey awarded $20 million in compensatory damages and $27.5 million in punitive damages to plaintiffs against the company in a Vioxx-related personal injury case. Merck was recently down 4 cents, or 0.1%, to $44.25.

Elsewhere, PDL BioPharma (PDLI) was gaining 1.6% at $19.43. Amgen (AMGN) was higher by 1.4% at $61.54. King Pharmaceuticals (KG) was adding 1% at $18.83.

Among losers, Teva Pharmaceutical (TEVA) was off 1.5% at $36.06. Forest Labs (FRX) was recently losing 0.9% at $51.65. Schering-Plough (SGP) was lower by 0.2% at $23.91.

>To order reprints of this article, click here: Reprints